Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
WuXi AppTec Co., Ltd. Class H ( (HK:2359) ) has provided an announcement.
WuXi AppTec plans to issue RMB6.78 billion of U.S. dollar-settled zero coupon convertible bonds due 2027, under a subscription agreement signed with a syndicate of managers after market close on May 14, 2026. The bonds are convertible into H shares at an initial price of HK$153.00, representing a premium to recent market prices, with potential conversion into about 51.1 million H shares and corresponding dilution to existing holders.
Estimated gross proceeds of about US$1.034 billion and net proceeds of about US$1.023 billion will be raised, to be used as outlined by the company, with conversion shares issued under an existing general mandate and not requiring further shareholder approval. The company has secured the required NDRC certificate and plans to list the bonds on the Vienna Stock Exchange and the conversion shares in Hong Kong, while cautioning investors that completion is subject to conditions and the deal may not close.
The most recent analyst rating on (HK:2359) stock is a Buy with a HK$169.40 price target. To see the full list of analyst forecasts on WuXi AppTec Co., Ltd. Class H stock, see the HK:2359 Stock Forecast page.
More about WuXi AppTec Co., Ltd. Class H
WuXi AppTec Co., Ltd. is a China-based pharmaceutical and life science services provider, offering research, development and manufacturing support to global healthcare and biotech companies. Its H shares are listed in Hong Kong, giving international investors exposure to the company’s contract research and development-driven growth in the healthcare sector.
Average Trading Volume: 4,711,276
Technical Sentiment Signal: Buy
Current Market Cap: HK$376.5B
See more data about 2359 stock on TipRanks’ Stock Analysis page.